In the present study, we identified a new tumor-associated CTL epitope (peptide A) derived from EML4-ALK, which binds to HLA-A*02:01 molecules, and we were able to establish a peptide-specific CTL clone from human PBMCs that specifically recognized cognate peptide-pulsed T2 cells and HLA-A*02:01 tumor cells expressing EML4-ALK that had been pretreated with IFN-γ. This evidence concerns the gene IFNG and neoplasm.